Jennifer Champoux Sells 2,176 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock

Posted by Stanley Muller on Jun 20th, 2026

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Get Free Report) COO Jennifer Champoux sold 2,176 shares of the business’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $19.00, for a total transaction of $41,344.00. Following the completion of the transaction, the chief operating officer owned 62,371 shares in the company, valued at $1,185,049. The trade was a 3.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Jennifer Champoux also recently made the following trade(s):

On Wednesday, May 27th, Jennifer Champoux sold 2,175 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $20.00, for a total value of $43,500.00.

Monte Rosa Therapeutics Stock Performance

Shares of NASDAQ:GLUE opened at $18.31 on Friday. The company has a market capitalization of $1.55 billion, a price-to-earnings ratio of -12.37 and a beta of 1.60. Monte Rosa Therapeutics, Inc. has a 12-month low of $4.12 and a 12-month high of $25.77. The business has a 50-day moving average price of $18.65 and a 200 day moving average price of $18.48.

Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). The company had revenue of $4.21 million during the quarter, compared to analyst estimates of $10.95 million. Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. As a group, equities research analysts predict that Monte Rosa Therapeutics, Inc. will post -1.23 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on GLUE shares. JPMorgan Chase & Co. upped their price objective on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Weiss Ratings raised Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Wells Fargo & Company cut their target price on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. Wall Street Zen cut Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Finally, Guggenheim lowered their price target on Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a research report on Wednesday, March 18th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Monte Rosa Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $32.50.

Read Our Latest Report on Monte Rosa Therapeutics

Institutional Trading of Monte Rosa Therapeutics

Several hedge funds have recently made changes to their positions in the business. State Street Corp lifted its position in shares of Monte Rosa Therapeutics by 148.9% during the fourth quarter. State Street Corp now owns 2,107,480 shares of the company’s stock worth $33,045,000 after purchasing an additional 1,260,707 shares in the last quarter. MPM Bioimpact LLC acquired a new position in shares of Monte Rosa Therapeutics in the fourth quarter valued at approximately $18,399,000. AQR Capital Management LLC grew its holdings in shares of Monte Rosa Therapeutics by 459.4% in the second quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock valued at $5,791,000 after purchasing an additional 1,054,406 shares in the last quarter. Braidwell LP purchased a new stake in Monte Rosa Therapeutics during the 4th quarter worth approximately $14,870,000. Finally, Vestal Point Capital LP purchased a new stake in Monte Rosa Therapeutics during the 3rd quarter worth approximately $5,928,000. Institutional investors and hedge funds own 79.96% of the company’s stock.

Monte Rosa Therapeutics Company Profile

(Get Free Report)

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.